Antiviral Therapy

Journal

Publication Venue For

  • Evolution of HIV-1 drug resistance after virological failure of first-line antiretroviral therapy in Lusaka, Zambia.  24:291-300. 2019
  • Vitamin D does not modulate immune-mediated bone loss during ART initiation.  24:355-362. 2019
  • Longitudinal study of falls among HIV-infected and uninfected women: The role of cognition.  23:179-190. 2018
  • Patterns of efavirenz use as first-line antiretroviral therapy in the United States: 1999-2015.  23:363-372. 2018
  • Tenofovir disoproxil fumarate appears to disrupt the relationship of Vitamin D and parathyroid hormone.  23:623-6928. 2018
  • Falls among middle-aged women in the Women's Interagency HIV Study.  21:697-706. 2016
  • Low bone mineral density and risk of incident fracture in HIV-infected adults.  21:45-54. 2016
  • Sex differences in overall and cause-specific mortality among HIV-infected adults on antiretroviral therapy in Europe, Canada and the US.  20:21-28. 2015
  • Single dose peramivir for the treatment of acute seasonal influenza: Integrated analysis of efficacy and safety from two placebo-controlled trials.  20:709-719. 2015
  • Vitamin D3 supplementation increases fibroblast growth factor-23 in HIV-infected youths treated with tenofovir disoproxil fumarate.  19:613-618. 2014
  • The 'Red Queen' dilemma - Running to stay in the same place: Reflections on the evolutionary vector of HBV in humans.  18:489-496. 2013
  • Disparities in prevalence of key chronic diseases by gender and race/ethnicity among antiretroviraltreated HIV-infected adults in the US.  18:65-75. 2013
  • Late diagnosis, delayed presentation and late presentation in HIV: Proposed definitions, methodological considerations and health implications.  18:17-23. 2013
  • HIV infection and obesity: Where did all the wasting go?.  17:1281-1289. 2012
  • Risk factors for vitamin D deficiency and relationship with cardiac biomarkers, inflammation and immune restoration in HIV-infected youth.  17:1069-1078. 2012
  • Vitamin D is linked to carotid intima-media thickness and immune reconstitution in HIV-positive individuals.  16:555-563. 2011
  • Prognostic importance of anaemia in HIV type-1-infected patients starting antiretroviral therapy: Collaborative analysis of prospective cohort studies.  13:959-967. 2008
  • Intracellular nucleoside triphosphate concentrations in HIV-infected patients on dual nucleoside reverse transcriptase inhibitor therapy.  12:981-986. 2007
  • A randomized study of antiviral medication switch at lower- versus higher-switch thresholds: AIDS clinical trials group study A5115.  12:531-541. 2007
  • Design issues in initial HIV-treatment trials: Focus on ACTG A5095.  11:751-760. 2006
  • Current status and future prospects of therapeutic drug monitoring and applied clinical pharmacology in antiretroviral therapy.  10:375-392. 2005
  • Therapeutic drug monitoring and drug-drug interactions involving antiretroviral drugs.  10:469-477. 2005
  • Polyphenotypic expression of mitochondrial toxicity caused by nucleoside reverse transcriptase inhibitors.  8:253-257. 2003
  • Single-dose pharmacokinetics of enteric-coated didanosine in HIV-infected children.  7:267-270. 2002
  • A dose-ranging study to evaluate the antiretroviral activity and safety of amprenavir alone and in combination with abacavir in HIV-infected adults with limited antiretroviral experience.  6:89-96. 2001
  • The management of herpesvirus infections in individuals with human immunodeficiency virus or AIDS.  2:25-28. 1997

    • International Standard Serial Number (issn)

  • 1359-6535

    • Electronic International Standard Serial Number (eissn)

  • 2040-2058